Ionis Enlists Bicycle To Open Up New Antisense Targets In Bounce-Back Bid
Aiming To Cross Blood Brain Barrier
Small-molecule drug delivery tech could help Ionis deliver its oligonucleotides where others cannot reach.
You may also be interested in...
Pharma moves Phase III-ready antibody to prevent pneumonia to Aridis, licenses preclinical STING inhibitors from F-star. Sanofi teams with SRI on AI-directed discovery, Biogen licenses BTK inhibitor from InnoCare.
Roche’s Phase III of tominersen in Huntington's disease has been stopped after an independent interim review, but with no new or emerging safety signals reported, analysts presume efficacy was the problem.
After multiple failed attempts to treat rare conditions, Marinus is on the cusp of success with ganaxolone in genetic epilepsy, and has secured a new European partner in Orion.